Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193596 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
A Phase 3 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 3
- Development phase
- 198
- Enrollment target
NCT00193596 is a Phase 3 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 198 participants.
The verdict
NCT00193596, a Phase 3 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 198 participants
- Enrollment target
Study Summary
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Etoposide
- DRUG Gemcitabine
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193596
The ClinicalTrials.gov registry entry for NCT00193596 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00193596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193596 about?
NCT00193596 is a clinical study titled "Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site". In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
What is the current status of trial NCT00193596?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 198 participants. The study started on 2003-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00193596?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Etoposide (DRUG), Gemcitabine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00193596?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.